These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

299 related items for PubMed ID: 10229902

  • 1. Growth hormone treatment of osteoporotic postmenopausal women - a one-year placebo-controlled study.
    Sääf M, Hilding A, Thorën M, Troell S, Hall K.
    Eur J Endocrinol; 1999 May; 140(5):390-9. PubMed ID: 10229902
    [Abstract] [Full Text] [Related]

  • 2. Bone mineral content and bone metabolism during physiological GH treatment in GH-deficient adults--an 18-month randomised, placebo-controlled, double blinded trial.
    Sneppen SB, Hoeck HC, Kollerup G, Sørensen OH, Laurberg P, Feldt-Rasmussen U.
    Eur J Endocrinol; 2002 Feb; 146(2):187-95. PubMed ID: 11834427
    [Abstract] [Full Text] [Related]

  • 3. Skeletal effects of cyclic recombinant human growth hormone and salmon calcitonin in osteopenic postmenopausal women.
    Holloway L, Kohlmeier L, Kent K, Marcus R.
    J Clin Endocrinol Metab; 1997 Apr; 82(4):1111-7. PubMed ID: 9100582
    [Abstract] [Full Text] [Related]

  • 4. Effects of growth hormone (GH) replacement on bone metabolism and mineral density in adult onset of GH deficiency: results of a double-blind placebo-controlled study with open follow-up.
    Finkenstedt G, Gasser RW, Höfle G, Watfah C, Fridrich L.
    Eur J Endocrinol; 1997 Mar; 136(3):282-9. PubMed ID: 9100553
    [Abstract] [Full Text] [Related]

  • 5. Influence of growth hormone on whole body and regional soft tissue composition in adult patients on hemodialysis. A double-blind, randomized, placebo-controlled study.
    Hansen TB, Gram J, Jensen PB, Kristiansen JH, Ekelund B, Christiansen JS, Pedersen FB.
    Clin Nephrol; 2000 Feb; 53(2):99-107. PubMed ID: 10711411
    [Abstract] [Full Text] [Related]

  • 6. Serum levels of insulin-like growth factor binding proteins (IGFBP)-4 and -5 correlate with bone mineral density in growth hormone (GH)-deficient adults and increase with GH replacement therapy.
    Thorén M, Hilding A, Brismar T, Magnusson P, Degerblad M, Larsson L, Sääf M, Baylink DJ, Mohan S.
    J Bone Miner Res; 1998 May; 13(5):891-9. PubMed ID: 9610754
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Growth hormone replacement therapy improves body composition and increases bone metabolism in elderly patients with pituitary disease.
    Fernholm R, Bramnert M, Hägg E, Hilding A, Baylink DJ, Mohan S, Thorén M.
    J Clin Endocrinol Metab; 2000 Nov; 85(11):4104-12. PubMed ID: 11095440
    [Abstract] [Full Text] [Related]

  • 10. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women.
    Murphy MG, Weiss S, McClung M, Schnitzer T, Cerchio K, Connor J, Krupa D, Gertz BJ, MK-677/Alendronate Study Group.
    J Clin Endocrinol Metab; 2001 Mar; 86(3):1116-25. PubMed ID: 11238495
    [Abstract] [Full Text] [Related]

  • 11. Short-term growth hormone treatment in girls with Turner syndrome decreases fat mass and insulin sensitivity: a randomized, double-blind, placebo-controlled, crossover study.
    Gravholt CH, Naeraa RW, Brixen K, Kastrup KW, Mosekilde L, Jørgensen JO, Christiansen JS.
    Pediatrics; 2002 Nov; 110(5):889-96. PubMed ID: 12415026
    [Abstract] [Full Text] [Related]

  • 12. Withdrawal of long-term physiological growth hormone (GH) administration: differential effects on bone density and body composition in men with adult-onset GH deficiency.
    Biller BM, Sesmilo G, Baum HB, Hayden D, Schoenfeld D, Klibanski A.
    J Clin Endocrinol Metab; 2000 Mar; 85(3):970-6. PubMed ID: 10720025
    [Abstract] [Full Text] [Related]

  • 13. Age-dependent changes in body composition in postmenopausal Japanese women: relationship to growth hormone secretion as well as serum levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3.
    Sugimoto T, Nakaoka D, Nasu M, Kanzawa M, Sugishita T, Chihara K.
    Eur J Endocrinol; 1998 Jun; 138(6):633-9. PubMed ID: 9678529
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Safety and efficacy of growth hormone (GH) during extended treatment of adult Japanese patients with GH deficiency (GHD).
    Chihara K, Kato Y, Kohno H, Takano K, Tanaka T, Teramoto A, Shimatsu A.
    Growth Horm IGF Res; 2008 Aug; 18(4):307-17. PubMed ID: 18282776
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Serum insulin-like growth factor I (IGF-I), IGF-binding protein-1 and -3, and the acid-labile subunit as serum markers of body composition during growth hormone (GH) therapy in adults with GH deficiency.
    Thorén M, Hilding A, Baxter RC, Degerblad M, Wivall-Helleryd IL, Hall K.
    J Clin Endocrinol Metab; 1997 Jan; 82(1):223-8. PubMed ID: 8989263
    [Abstract] [Full Text] [Related]

  • 18. Effects of 42 months of GH treatment on bone mineral density and bone turnover in GH-deficient adults.
    Välimäki MJ, Salmela PI, Salmi J, Viikari J, Kataja M, Turunen H, Soppi E.
    Eur J Endocrinol; 1999 Jun; 140(6):545-54. PubMed ID: 10377504
    [Abstract] [Full Text] [Related]

  • 19. Two years of treatment with recombinant human growth hormone increases bone mineral density in men with idiopathic osteoporosis.
    Gillberg P, Mallmin H, Petrén-Mallmin M, Ljunghall S, Nilsson AG.
    J Clin Endocrinol Metab; 2002 Nov; 87(11):4900-6. PubMed ID: 12414848
    [Abstract] [Full Text] [Related]

  • 20. Effect of recombinant human growth hormone in elderly osteoporotic women.
    Sugimoto T, Nakaoka D, Nasu M, Kanzawa M, Sugishita T, Chihara K.
    Clin Endocrinol (Oxf); 1999 Dec; 51(6):715-24. PubMed ID: 10619976
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.